WO2011091807A1 - Anticoagulant et glutathion pour le traitement du cancer - Google Patents

Anticoagulant et glutathion pour le traitement du cancer Download PDF

Info

Publication number
WO2011091807A1
WO2011091807A1 PCT/EG2010/000004 EG2010000004W WO2011091807A1 WO 2011091807 A1 WO2011091807 A1 WO 2011091807A1 EG 2010000004 W EG2010000004 W EG 2010000004W WO 2011091807 A1 WO2011091807 A1 WO 2011091807A1
Authority
WO
WIPO (PCT)
Prior art keywords
glutathione
cytochrome
cancer
anticoagulant
treatment
Prior art date
Application number
PCT/EG2010/000004
Other languages
English (en)
Inventor
Abdelrahman Shata Mohammed Shata
Original Assignee
Abdelrahman Shata Mohammed Shata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abdelrahman Shata Mohammed Shata filed Critical Abdelrahman Shata Mohammed Shata
Publication of WO2011091807A1 publication Critical patent/WO2011091807A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione

Definitions

  • the target is how to clear and heal by a certain treatment or medication the hereditary diseases of cancer.
  • the xenobiotices are substances parallel to the foreign bodies in the meaning from the side of attacking mechanism to the human certain organs, which well be delayed and destroyed by the defense mechanism and immune system as one of the most important vital processes occurring continuously thousand of times at human system.
  • Cytochrome P450s are immunity workers which work at two completely deferent directions and opposite benefits. - Specific way from general malignancy starting substances :
  • eating of half cooked liver will lead to non completed digestion of hepatic proteins and absorption of many amino acids attached together by poly peptide chains into circulation may occur.
  • the immunity system will deal with them as foreign bodies because the body doesn't recognize any protein except when it destructed into amino acids.
  • the undifferentiated stem cells may mutate according to the genetic code of those amino acids resulting in increasing amount of cells acting exactly the same action of those amino acids.
  • the protein may binds to cytochrome p450s without the attachment of glutathione to this complex ( look at the details in the next subtitle ).
  • the planning pathway of the war zone beginning from entering the body terminal to their destruction is as next :
  • xenobiotic bodies enter the body and they will be hosted by cytochrome P450s to be converted to reactive metabolites which will bind as soon as possible with glutathione (which are normal bodies present in blood and is secreted from liver ) which will convert the xenobiotics cytochrome complex to non toxic material and harmless to the body by the excretion of this complex with glutathione in urine.
  • glutathione which are normal bodies present in blood and is secreted from liver
  • the result will be nothing but three, to produce cell injury directly, binding with a substance called hapten which will produces also cell injury, or activation of mutation process leading to formation of malignancy.
  • a medical information says that the anticoagulant medication exhausts the cytochrome P450s leading to their consumption. So, we will use warrfarine as one of the anticoagulant medications to make the cytochrome P450s busy with it in replacement of supplying the malignant compounds.
  • the immunity also plays a very important role to accelerate the process of healing. So, the most important thing to feed the immunity is the feeling of care by the patient's family.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Le cancer peut être traité par l'utilisation de médicaments anticoagulants tels que la warfarine pour consommer autant que possible du cytochrome P450s et ensuite, l'administration de glutathion dans des doses spécifiques pour consommer le reste du cytochrome P 450s en remplacement de l'approvisionnement en composé malin. Le patient sera accueilli dans une pièce stabilisée isolée avec des soins médicaux à cause de l'effet secondaire des médicaments appliqués.
PCT/EG2010/000004 2010-01-31 2010-02-03 Anticoagulant et glutathion pour le traitement du cancer WO2011091807A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2010010162 2010-01-31
EG2010010162 2010-01-31

Publications (1)

Publication Number Publication Date
WO2011091807A1 true WO2011091807A1 (fr) 2011-08-04

Family

ID=44318684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2010/000004 WO2011091807A1 (fr) 2010-01-31 2010-02-03 Anticoagulant et glutathion pour le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2011091807A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204248B1 (en) * 1996-12-31 2001-03-20 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO2001080849A1 (fr) * 2000-04-26 2001-11-01 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Methode de traitement anticancereux
US20070026077A1 (en) * 2003-10-17 2007-02-01 Alas Franc Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
US20080138395A1 (en) * 2005-02-14 2008-06-12 Treusch Gernot Pharmaceutical Composition for the Prevention and Control of Cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204248B1 (en) * 1996-12-31 2001-03-20 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO2001080849A1 (fr) * 2000-04-26 2001-11-01 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Methode de traitement anticancereux
US20070026077A1 (en) * 2003-10-17 2007-02-01 Alas Franc Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
US20080138395A1 (en) * 2005-02-14 2008-06-12 Treusch Gernot Pharmaceutical Composition for the Prevention and Control of Cancer

Similar Documents

Publication Publication Date Title
RU2139085C1 (ru) Средство, стимулирующее репаративные процессы, и способ его применения
EP2191836B1 (fr) Agent destiné à la prophylaxie ou au soulagement d'un trouble nerveux périphérique induit par un agent anti-cancéreux
Chakraborty et al. Aqueous extract of human placenta as a therapeutic agent
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
JP2015502135A5 (fr)
Vasilets et al. Plasma medicine
WO2011091807A1 (fr) Anticoagulant et glutathion pour le traitement du cancer
Dindar et al. Efect of dual growth factor administration on oxidative markers during acute stage wound healing in rats
CN109288842A (zh) 铁剂在提升缺铁性贫血病人b细胞水平中的应用
Chen et al. Schwann cell‐derived amphiregulin enhances nerve regeneration via supporting the proliferation and migration of Schwann cells and the elongation of axons
US20040076618A1 (en) Placental preparation having antitumor activity
Tenka Sarcodes and its homoeopathic application
Rebryk et al. Тhe use of nanotechnology in the treatment of cancer
Tallberg Regulation of cancer by therapeutic vaccination and dietary bio-modulation involving organ-specific mitochondria
Sass et al. Examination of epigenetic inhibitor zebularine in treatment of skin wounds in healthy and diabetic mice
Shraddhamayananda Alternative medical management of localized skin hypopigmentation by homeopathic medicinea breakthrough in medical management
CZ21045U1 (cs) Imunomodulační biokompozice s regeneračním a vitalizačním účinkem
CN116077503A (zh) Mettl3酶抑制剂在制备白癜风药物中的应用及其药物
CN111821442A (zh) 一种治疗和/或预防银杏花粉过敏性疾病的物质及其设计方法和制备方法
Wolchok Cancer’s Off Switch
RU2414890C1 (ru) Способ лечения перстневидноклеточного рака желудка
Ostanin Controlled Eosinophilic Syndrome Against Cancer. Scientific Discovery and Practical Aspects of Immunotherapy
Jere Effect of Photobiomudulation at 660 Nm on the Jak/Stat Signalling Pathway in Diabetic Wounded Cells
Divocha The Influence of Polarized Light in Defenses of Mice Infected with a Lethal Dose of Influenza A Virus
Holovach et al. Porphyria: pathogenetic pharmacotherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10844485

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10844485

Country of ref document: EP

Kind code of ref document: A1